

RMBCC LEARNING OBJECTIVES

Goal: To educate oncology nurses, social workers, and other healthcare professionals about the treatment and management of blood cancer, and support available for blood cancer patients and professionals.

Taking the Mystery Out of Cancer Clinical Trials

- Express an understanding of the cancer clinical trial process
- Explain nurse and social worker roles in preparing patients to consider a clinical trial
- Describe The Leukemia & Lymphoma Society's role in increasing access to clinical trials

Compassion Fatigue; Fostering Resilience and Sustainability in Oncology Professionals

- Demonstrate an understanding of compassion fatigue and its core components
- Differentiate the risk factors for, and warning signs of, compassion fatigue
- Examine specific evidence-based strategies for reducing compassion fatigue and increasing resilience and sustainability

An Introduction to Clinical Immunotherapy: The Agents and The Issues

- Describe immunotherapy as a blood cancer treatment modality
- List the types of immunotherapeutic agents as well as the risks and side effects associated with each
- Determine the appropriate management of patient receiving immunotherapies
- Differentiate the immune-associated complications of other non-immunotherapeutic agents

Myeloma: Managing Toxicity & Side Effects of Therapy

- Demonstrate an understanding of the common toxicities seen with the most widely used agents in multiple myeloma
- Classify the toxicities seen with the newly approved drugs in multiple myeloma: monoclonal antibodies, Bcl-2 inhibitors, next generation immunomodulatory drugs and proteasome inhibitors.
- Identify the common toxicities seen with autologous stem cell transplantation
- Determine how to effectively manage or mitigate the toxicities of myeloma therapy

Target Audience: Oncology nurses and social workers at all levels and licensure, and other healthcare professionals involved in the treatment of patients with blood cancer.

Approval for nurses has been obtained by the National Office of *The Leukemia & Lymphoma Society* under provider number CEP 5832 to award 4.0 continuing education contact hours through the California Board of Registered Nursing.

The Leukemia & Lymphoma Society (LLS), provider #1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org Approved Continuing Education Program (ACE). Approval Period: December 2017 - December 2020. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 4.0 CE (clinical) contact hours.

Upon completion of this conference and submission of the activity evaluation, a certificate of completion will be issued to you within 30 days.